We are only able to display limited information for this firm. We display more complete information for all of the following firms:

Praised for its ‘excellent knowledge, responsiveness, and practical support’, Cooley (UK) LLP has extensive experience in complex, cross-border transactions involving a global roster investors, chiefly in the tech and life science sectors. The team regularly advises clients on both financing and funding rounds, while offering a tailored service on all elements of IP, tax, and litigation. The group is co-chaired by Ryan Naftulin and Aaron Archer, the pair are hailed for their expertise in the disruptive tech arena, frequently supporting investors with equity financings and corporate advisory work. Tom Goodman is knowledgeable in Series A financing rounds. Eric Davison, Kerry Corrigan, and Ellen Dewhurst are all further core members of the venture capital practice. The group was recently bolstered by the arrival of Angus Miln, Ali Ramadan, and Helen Pantelides, who arrived from Taylor Wessing, Goodwin, and White & Case, respectively.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

  • ‘Cooley have advised us for all corporate matters for the last 3 years - funding rounds, strategic investments, secondary transactions and the recent departures of two of our founders. Their advice is timely, commercial and technically excellent. I love having Cooley on my side and they are a great support to me as a GC with an incredibly lean team.’

  • ‘Eric Davison and Aaron Archer are the team that support us. Aaron is great and very present, but Eric is truly excellent. I am not looking forward to the day he is promoted to partner as our fees will increase and he'll do less of the work!’

Abbreviated data is displayed for this firm.

Key clients

  • Synthesia
  • Raft
Abbreviated data is displayed for this firm.

Work highlights

  • Advised Synthesia, the world’s leading generative AI video creation platform for enterprises, on its $90m Series C funding, valuing the company at $1bn (the latest UK based Unicorn).
  • Advised EyeBiotech on a $130m Series A financing round.
Abbreviated data is displayed for this firm.